Skip to content

Primary Angle Closure Glaucoma and Aqueous Dynamics

A Randomised Comparative Study of the Effects of Cataract Extraction With Lens Implant Alone Versus Cataract Extraction With Lens Implant and Goniosynechialysis on Outflow Facility in Patients With Primary Angle Closure Glaucoma.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00719290
Enrollment
24
Registered
2008-07-21
Start date
2008-07-31
Completion date
2015-08-31
Last updated
2015-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Angle Closure

Keywords

Primary Angle Closure Glaucoma, Phacoemulsification, Goniosynechialysis, Outflow facility

Brief summary

The aim of the study is to determine which is the best treatment for people with cataract and primary angle closure (PAC).In PAC, apposition of the iris tissue to the drainage channels (Trabecular Meshwork-TM) of the eye results in damage and formation of adherences between these structures (Peripheral anterior synaechiae-PAS) causing a mechanical obstruction of the aqueous outflow via the TM. It is thought that cataract surgery combined with mechanical separation of the iris from the TM with the breakage of PAS(we call this separation 'goniosynechialysis') would make the pressure even lower as it would cause the drain to open to a greater extent than cataract surgery alone. This technique is not new, and the results have been very encouraging. Comparing this technique to cataract surgery alone however, has not been done and this is exactly what we would like to do in order to help us decide what is the best treatment. In summary, the investigators propose that cataract surgery with goniosynechialysis would lower intraocular pressure to a greater extent than cataract surgery alone in patients with significant PAS.

Interventions

PROCEDUREPhacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)

Phacoemulsification of the lens with intraocular lens implant

PROCEDUREPhacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)

Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis

Sponsors

Guy's and St Thomas' NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 21 years. * Diagnosis of PAC or PACG. PACG is defined as glaucomatous optic neuropathy in the opinion of a fellowship-trained glaucoma specialist, together with an IOP \> 21mmHg on at least one occasion, and reproducible visual field defect (using the 24-2 test pattern on a Humphrey Field Analyser). PAC has all the above characteristics except for the visual field defect. * More than 90 degrees of PAS (not necessarily contiguous). * Lens opacity deemed sufficient to be causing decreased vision in the opinion of the supervising consultant (KSL). * Ability to give informed consent.

Exclusion criteria

* Previous intraocular surgery or keratorefractive surgery. * Previous eye trauma resulting in documented damage to the drainage angle (such as angle recession). * History of uveitis. * For patients on warfarin, INR \>3.0 on day of surgery. * Anterior segment neovascularisation. * Chronic use of topical or systemic steroids.

Design outcomes

Primary

MeasureTime frame
1. Outflow facility Success defined as increased outflow facility at 3 month compared to baseline with the same or reduced number of intraocular pressure lowering medications.3 months

Secondary

MeasureTime frame
1. Intraocular pressure Success defined as decreased IOP at 3 month compared to baseline with the same or reduced number of intraocular pressure lowering medications3 months
Intra- or post operative complications2-3 weeks
Long-term PAS development1 year

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026